Impact of Coexisting Gene Mutations in EGFR-Mutated Non –Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs

Recent insight into the molecular basis of lung cancer has led to changes in the treatment of this disease. The identification of driver mutations, such as those affecting the epidermal growth factor receptor (EGFR)[1,2] and anaplastic lymphoma kinase (ALK) genes [3], has already been successfully translated into clinical practice. However, whereas most individuals with non –small cell lung cancer (NSCLC) who harbor sensitizing EGFR mutations show an initial marked response to 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs), all such patients ultimately develop acquired resistance to these drugs within 9 to 14 months after therapy initiation [4–7].

Source: Lung Cancer - November 2, 2019 Category: Cancer & Oncology Authors: Masayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Koji Haratani, Takayuki Takahama, Ryoji Kato, Kimio Yonesaka, Kazuto Nishio, Kazuhiko Nakagawa Source Type: research